Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Three-peptide blend · GHK-Cu / BPC-157 / TB-500
A three-peptide blend of GHK-Cu, BPC-157 and TB-500 in a single fill. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Three peptides in a single fill: GHK-Cu, BPC-157, TB-500. They arrive from three unrelated repair literatures — GHK-Cu from copper-driven matrix and collagen work, BPC-157 from angiogenesis and the nitric-oxide axis, TB-500 from actin sequestration and cell migration.
Co-formulating collapses all three onto one preparation. Overlap is the entire point: a lab watches matrix, vascular, and cytoskeletal responses inside the same sample rather than reconstructing the picture from three vials run apart.
Evidence accrues component by component: GHK-Cu on collagen and matrix output, BPC-157 across tendon and vascular repair, thymosin β4 / TB-500 on wound closure and migration. The blend contributes one further question — whether matrix, angiogenic, and cytoskeletal effects sum, cancel, or read independently when held in a single model.
Each of the three carries a separate evidence base into the vial. GHK-Cu reads through collagen and matrix synthesis in fibroblast and wound preparations; BPC-157 through angiogenesis and connective-tissue repair; TB-500, a thymosin β4 fragment, through actin regulation and wound closure.
The blend is the intersection of those three records. Held in one preparation, it lets a single sample report matrix, vascular, and cytoskeletal effects at once — which is the case for combining them rather than running three samples in parallel.
Nothing about the three is shared at the origin. GHK came out of human-plasma fractionation in the 1970s; BPC-157 out of gastric-juice peptide screening in the early 1990s; TB-500 out of the thymosin β4 work on cytoskeletal dynamics.
Fixing them at one ratio is a matter of experimental economy — a single preparation that carries all three repair mechanisms into the same controlled run instead of three.
Pickart, L. (2008). The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 19(8):969–988.
PubMedSikirić, P. et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 87(5):313–327.
PubMedGoldstein, A.L. et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 12(1):37–51.
PubMedMalinda, K.M. et al. (1999). Thymosin beta4 accelerates wound healing. J Invest Dermatol 113(3):364–368.
PubMedIndependent testing lot by lot: identity, purity, net content. The certificate arrives by email with your order.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
